Cargando…

Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure

BACKGROUND: Metabolic impairment is an important contributor to heart failure (HF) pathogenesis and progression. Dysregulated metabolic pathways remain poorly characterized in patients with HF and preserved ejection fraction (HFpEF). We sought to determine metabolic abnormalities in HFpEF and identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunter, Wynn G., Kelly, Jacob P., McGarrah, Robert W., Khouri, Michel G., Craig, Damian, Haynes, Carol, Ilkayeva, Olga, Stevens, Robert D., Bain, James R., Muehlbauer, Michael J., Newgard, Christopher B., Felker, G. Michael, Hernandez, Adrian F., Velazquez, Eric J., Kraus, William E., Shah, Svati H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015273/
https://www.ncbi.nlm.nih.gov/pubmed/27473038
http://dx.doi.org/10.1161/JAHA.115.003190
_version_ 1782452406200565760
author Hunter, Wynn G.
Kelly, Jacob P.
McGarrah, Robert W.
Khouri, Michel G.
Craig, Damian
Haynes, Carol
Ilkayeva, Olga
Stevens, Robert D.
Bain, James R.
Muehlbauer, Michael J.
Newgard, Christopher B.
Felker, G. Michael
Hernandez, Adrian F.
Velazquez, Eric J.
Kraus, William E.
Shah, Svati H.
author_facet Hunter, Wynn G.
Kelly, Jacob P.
McGarrah, Robert W.
Khouri, Michel G.
Craig, Damian
Haynes, Carol
Ilkayeva, Olga
Stevens, Robert D.
Bain, James R.
Muehlbauer, Michael J.
Newgard, Christopher B.
Felker, G. Michael
Hernandez, Adrian F.
Velazquez, Eric J.
Kraus, William E.
Shah, Svati H.
author_sort Hunter, Wynn G.
collection PubMed
description BACKGROUND: Metabolic impairment is an important contributor to heart failure (HF) pathogenesis and progression. Dysregulated metabolic pathways remain poorly characterized in patients with HF and preserved ejection fraction (HFpEF). We sought to determine metabolic abnormalities in HFpEF and identify pathways differentially altered in HFpEF versus HF with reduced ejection fraction (HFrEF). METHODS AND RESULTS: We identified HFpEF cases, HFrEF controls, and no‐HF controls from the CATHGEN study of sequential patients undergoing cardiac catheterization. HFpEF cases (N=282) were defined by left ventricular ejection fraction (LVEF) ≥45%, diastolic dysfunction grade ≥1, and history of HF; HFrEF controls (N=279) were defined similarly, except for having LVEF <45%. No‐HF controls (N=191) had LVEF ≥45%, normal diastolic function, and no HF diagnosis. Targeted mass spectrometry and enzymatic assays were used to quantify 63 metabolites in fasting plasma. Principal components analysis reduced the 63 metabolites to uncorrelated factors, which were compared across groups using ANCOVA. In basic and fully adjusted models, long‐chain acylcarnitine factor levels differed significantly across groups (P<0.0001) and were greater in HFrEF than HFpEF (P=0.0004), both of which were greater than no‐HF controls. We confirmed these findings in sensitivity analyses using stricter inclusion criteria, alternative LVEF thresholds, and adjustment for insulin resistance. CONCLUSIONS: We identified novel circulating metabolites reflecting impaired or dysregulated fatty acid oxidation that are independently associated with HF and differentially elevated in HFpEF and HFrEF. These results elucidate a specific metabolic pathway in HF and suggest a shared metabolic mechanism in HF along the LVEF spectrum.
format Online
Article
Text
id pubmed-5015273
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50152732016-09-19 Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure Hunter, Wynn G. Kelly, Jacob P. McGarrah, Robert W. Khouri, Michel G. Craig, Damian Haynes, Carol Ilkayeva, Olga Stevens, Robert D. Bain, James R. Muehlbauer, Michael J. Newgard, Christopher B. Felker, G. Michael Hernandez, Adrian F. Velazquez, Eric J. Kraus, William E. Shah, Svati H. J Am Heart Assoc Original Research BACKGROUND: Metabolic impairment is an important contributor to heart failure (HF) pathogenesis and progression. Dysregulated metabolic pathways remain poorly characterized in patients with HF and preserved ejection fraction (HFpEF). We sought to determine metabolic abnormalities in HFpEF and identify pathways differentially altered in HFpEF versus HF with reduced ejection fraction (HFrEF). METHODS AND RESULTS: We identified HFpEF cases, HFrEF controls, and no‐HF controls from the CATHGEN study of sequential patients undergoing cardiac catheterization. HFpEF cases (N=282) were defined by left ventricular ejection fraction (LVEF) ≥45%, diastolic dysfunction grade ≥1, and history of HF; HFrEF controls (N=279) were defined similarly, except for having LVEF <45%. No‐HF controls (N=191) had LVEF ≥45%, normal diastolic function, and no HF diagnosis. Targeted mass spectrometry and enzymatic assays were used to quantify 63 metabolites in fasting plasma. Principal components analysis reduced the 63 metabolites to uncorrelated factors, which were compared across groups using ANCOVA. In basic and fully adjusted models, long‐chain acylcarnitine factor levels differed significantly across groups (P<0.0001) and were greater in HFrEF than HFpEF (P=0.0004), both of which were greater than no‐HF controls. We confirmed these findings in sensitivity analyses using stricter inclusion criteria, alternative LVEF thresholds, and adjustment for insulin resistance. CONCLUSIONS: We identified novel circulating metabolites reflecting impaired or dysregulated fatty acid oxidation that are independently associated with HF and differentially elevated in HFpEF and HFrEF. These results elucidate a specific metabolic pathway in HF and suggest a shared metabolic mechanism in HF along the LVEF spectrum. John Wiley and Sons Inc. 2016-07-29 /pmc/articles/PMC5015273/ /pubmed/27473038 http://dx.doi.org/10.1161/JAHA.115.003190 Text en © 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Hunter, Wynn G.
Kelly, Jacob P.
McGarrah, Robert W.
Khouri, Michel G.
Craig, Damian
Haynes, Carol
Ilkayeva, Olga
Stevens, Robert D.
Bain, James R.
Muehlbauer, Michael J.
Newgard, Christopher B.
Felker, G. Michael
Hernandez, Adrian F.
Velazquez, Eric J.
Kraus, William E.
Shah, Svati H.
Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure
title Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure
title_full Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure
title_fullStr Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure
title_full_unstemmed Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure
title_short Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure
title_sort metabolomic profiling identifies novel circulating biomarkers of mitochondrial dysfunction differentially elevated in heart failure with preserved versus reduced ejection fraction: evidence for shared metabolic impairments in clinical heart failure
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015273/
https://www.ncbi.nlm.nih.gov/pubmed/27473038
http://dx.doi.org/10.1161/JAHA.115.003190
work_keys_str_mv AT hunterwynng metabolomicprofilingidentifiesnovelcirculatingbiomarkersofmitochondrialdysfunctiondifferentiallyelevatedinheartfailurewithpreservedversusreducedejectionfractionevidenceforsharedmetabolicimpairmentsinclinicalheartfailure
AT kellyjacobp metabolomicprofilingidentifiesnovelcirculatingbiomarkersofmitochondrialdysfunctiondifferentiallyelevatedinheartfailurewithpreservedversusreducedejectionfractionevidenceforsharedmetabolicimpairmentsinclinicalheartfailure
AT mcgarrahrobertw metabolomicprofilingidentifiesnovelcirculatingbiomarkersofmitochondrialdysfunctiondifferentiallyelevatedinheartfailurewithpreservedversusreducedejectionfractionevidenceforsharedmetabolicimpairmentsinclinicalheartfailure
AT khourimichelg metabolomicprofilingidentifiesnovelcirculatingbiomarkersofmitochondrialdysfunctiondifferentiallyelevatedinheartfailurewithpreservedversusreducedejectionfractionevidenceforsharedmetabolicimpairmentsinclinicalheartfailure
AT craigdamian metabolomicprofilingidentifiesnovelcirculatingbiomarkersofmitochondrialdysfunctiondifferentiallyelevatedinheartfailurewithpreservedversusreducedejectionfractionevidenceforsharedmetabolicimpairmentsinclinicalheartfailure
AT haynescarol metabolomicprofilingidentifiesnovelcirculatingbiomarkersofmitochondrialdysfunctiondifferentiallyelevatedinheartfailurewithpreservedversusreducedejectionfractionevidenceforsharedmetabolicimpairmentsinclinicalheartfailure
AT ilkayevaolga metabolomicprofilingidentifiesnovelcirculatingbiomarkersofmitochondrialdysfunctiondifferentiallyelevatedinheartfailurewithpreservedversusreducedejectionfractionevidenceforsharedmetabolicimpairmentsinclinicalheartfailure
AT stevensrobertd metabolomicprofilingidentifiesnovelcirculatingbiomarkersofmitochondrialdysfunctiondifferentiallyelevatedinheartfailurewithpreservedversusreducedejectionfractionevidenceforsharedmetabolicimpairmentsinclinicalheartfailure
AT bainjamesr metabolomicprofilingidentifiesnovelcirculatingbiomarkersofmitochondrialdysfunctiondifferentiallyelevatedinheartfailurewithpreservedversusreducedejectionfractionevidenceforsharedmetabolicimpairmentsinclinicalheartfailure
AT muehlbauermichaelj metabolomicprofilingidentifiesnovelcirculatingbiomarkersofmitochondrialdysfunctiondifferentiallyelevatedinheartfailurewithpreservedversusreducedejectionfractionevidenceforsharedmetabolicimpairmentsinclinicalheartfailure
AT newgardchristopherb metabolomicprofilingidentifiesnovelcirculatingbiomarkersofmitochondrialdysfunctiondifferentiallyelevatedinheartfailurewithpreservedversusreducedejectionfractionevidenceforsharedmetabolicimpairmentsinclinicalheartfailure
AT felkergmichael metabolomicprofilingidentifiesnovelcirculatingbiomarkersofmitochondrialdysfunctiondifferentiallyelevatedinheartfailurewithpreservedversusreducedejectionfractionevidenceforsharedmetabolicimpairmentsinclinicalheartfailure
AT hernandezadrianf metabolomicprofilingidentifiesnovelcirculatingbiomarkersofmitochondrialdysfunctiondifferentiallyelevatedinheartfailurewithpreservedversusreducedejectionfractionevidenceforsharedmetabolicimpairmentsinclinicalheartfailure
AT velazquezericj metabolomicprofilingidentifiesnovelcirculatingbiomarkersofmitochondrialdysfunctiondifferentiallyelevatedinheartfailurewithpreservedversusreducedejectionfractionevidenceforsharedmetabolicimpairmentsinclinicalheartfailure
AT krauswilliame metabolomicprofilingidentifiesnovelcirculatingbiomarkersofmitochondrialdysfunctiondifferentiallyelevatedinheartfailurewithpreservedversusreducedejectionfractionevidenceforsharedmetabolicimpairmentsinclinicalheartfailure
AT shahsvatih metabolomicprofilingidentifiesnovelcirculatingbiomarkersofmitochondrialdysfunctiondifferentiallyelevatedinheartfailurewithpreservedversusreducedejectionfractionevidenceforsharedmetabolicimpairmentsinclinicalheartfailure